COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on May 7, 2024, it received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders' equity requirement. Nasdaq Listing Rule 5550(b)(1) require ...

Evaxion Biotech A/S (EVAX) , along with its undisclosed partner, announced the successful completion of a series of large non-rodent animal infection studies, testing antigens from its investigational EVX-B1 vaccine candidate, which is being developed to treat Staphylococcus aureus (S. aureus) infection.Per the companies, in the completed pre-clinical studies, treatment with EVX-B1 antigens significantly reduced the disease burden. Based on such positive results, Evaxion and its partner are currently discus ...

Evaxion Biotech A/S (EVAX) Q4 2023 Results Conference Call April 2, 2024 9:00 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Thomas Flaten - Lake Street Capital Markets Richard Ramanius - Redeye Christian Kanstrup Hello, everyone, and a very warm welcome to this Evaxion Busine ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology™ outcompetes standard vaccine target discovery approaches and holds the promise of addressing serious unmet needsWith a unique modular architecture, AI-Immunology™ is scalable and adaptable towards partner needsThe potential of AI-Immunology™ is validated by established partnerships, including an ongoing vaccine collaboration ...

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces that it will host a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST. The R&D Day will feature a series of talks from Evaxion's scientists and bioinformaticians, providing insights into ...

COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). Th ...

COPENHAGEN, Denmark, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing on February 5, 2024 of its previously announced public offering of 3,750,000 of its American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-fund ...

COPENHAGEN, Denmark, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-funded warrant in lieu thereof) ...

Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Conference Call August 22, 2023 10:00 AM ET Company Participants Per Norlen - Chief Executive Officer Jesper Nyegaard Nissen - Chief Operating Officer and Interim Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and thank you for standing by. Welcome to the Evaxion Biotech Q2 Results Call. At this time, all participants are in a listen-only mo ...